Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;38(6):1581-1582.
doi: 10.1111/pde.14853. Epub 2021 Nov 8.

Severe hypertriglyceridemia following sirolimus use in an infant

Hannah Clark  1 , Rachael Schulte  2 , Anita N Haggstrom  3
Affiliations

Severe hypertriglyceridemia following sirolimus use in an infant

Hannah Clark et al. Pediatr Dermatol. 2021 Nov.

Abstract

Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off-label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.

Keywords: arteriovenous malformation; triglycerides; vascular malformation.

PubMed Disclaimer

References

REFERENCES

    1. Vergès B, Walter T, Cariou B. Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol. 2014;170(2):R43-R55.
    1. Wang H, Guo X, Duan Y, Zheng B, Gao Y. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma. Pediatr Dermatol. 2018;35(5):635-638.
    1. Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018-1024.
    1. Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.
    1. Lai KC, Brothers JA, Stoller JZ. Severe hypertriglyceridemia associated with everolimus drug-eluting stent placement in an infant. Cardiol Young. 2019;29(4):541-543.

LinkOut - more resources